Insights That Move the GPCR Field Forward

The Gaps They Already See 👉 As a biotech founder, it’s easy to mistake volume for readiness . A solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels like you’re ready for that pre-IND meeting. And yet, many founders walk out of their first FDA conversation with a quiet sense of confusion . 👉 No dramatic rejection. No loud red flags.Just a series of subtle but firm questions pointing to what’s missing . While you’re focused on